Regulation of Inflammation by Sucrose Isomer, Turanose, in Raw 264.7 Cells.
10.15430/JCP.2017.22.3.195
- Author:
Joo Yeon CHUNG
1
;
Yoo Sun KIM
;
Yuri KIM
;
Sang Ho YOO
Author Information
1. Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, Korea. yuri.kim@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Turanose;
Sweetening agents;
Macrophages;
Inflammation
- MeSH:
Cell Survival;
Cytokines;
Glucose;
Honey;
In Vitro Techniques;
Inflammation*;
Interleukin-18;
Interleukins;
Macrophages;
Nitric Oxide;
Nitric Oxide Synthase Type II;
RAW 264.7 Cells*;
Risk Factors;
RNA, Messenger;
Sucrose*;
Superoxide Dismutase;
Sweetening Agents
- From:Journal of Cancer Prevention
2017;22(3):195-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
Increased sugar consumption has been proposed to be a risk factor for obesity-related metabolic disorders. The objective of this study was to investigate the anti-inflammatory effect of turanose in Raw 264.7 macrophages. Turanose (3-O-α-D-glucosyl-D-fructose), an isomer of sucrose, naturally exists in honey. For these studies, macrophages were treated with total glucose (Glu), 50% Glu/50% turanose (T50), 25% Glu/75% turanose (T75), and 100% turanose (T100), each with a total concentration of 25 mM in cell media. Expressions of inflammatory enzymes and cytokines were analyzed. Cell viability was not affected in the turanose treated groups compared to the Glu group. Lipopolysaccharide and glucose-induced nitric oxide production, protein expression of inducible nitric oxide synthase, COX-2, and superoxide dismutase 2, and mRNA expression levels of interleukin (IL)-1β and IL-18 were significantly suppressed by turanose treatment. These results demonstrate that turanose exerts anti-inflammatory effects in vitro, and possesses potential to serve therapeutic functional sweetener for testing in vivo and in clinical trials.
